Ticker Details
Iovance Biotherapeutics, Inc. Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases.
IPO Date:	October 23, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.98B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.50 | 3.73%
Avg Daily Range (30 D):	$0.30 | 5.01%
Avg Daily Range (90 D):	$0.21 | 4.33%

Institutional Daily Volume
Avg Daily Volume:	4.62M
Avg Daily Volume (30 D):	15.87M
Avg Daily Volume (90 D):	14.52M

Trade Size
Avg Trade Size (Sh.):	199
Avg Trade Size (Sh.) (30 D):	272
Avg Trade Size (Sh.) (90 D):	314

Institutional Trades
Total Institutional Trades:	5,802
Avg Institutional Trade:	$2.55M
Avg Institutional Trade (30 D):	$2.51M
Avg Institutional Trade (90 D):	$2.75M
Avg Institutional Trade Volume:	.26M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.94M
Avg Closing Trade (30 D):	$6.15M
Avg Closing Trade (90 D):	$5.31M
Avg Closing Volume:	428.83K

News

Sep 4, 2026 @ 12:00 PM Iovance Biotherapeutics to Present at Upcoming Con... Source: Na

Sep 3, 2026 @ 5:00 PM Advanced Endometrial Cancer Clinical Trial Pipelin... Source: Delveinsight

Aug 10, 2026 @ 7:29 PM Iovance Biotherapeutics Stock Soars After the Comp... Source: David Jagielski, Cpa

Jul 17, 2026 @ 9:15 PM Iovance Biotherapeutics Reports Inducement Grants ... Source: Na

Jun 23, 2026 @ 11:33 PM Amgen vs. Iovance Biotherapeutics: Which Healthcar... Source: Sara Appino

Financials
	TTM	Q1 2026	Q3 2025
Basic EPS	$-.11	$-.19	$-.25
Diluted EPS	$-.11	$-.19
Revenue	$99.31M	$71.43M	$67.46M
Gross Profit	$55.72M	$28.93M	$28.98M
Net Income / Loss	$-47.32M	$-79.05M	$-91.25M
Operating Income / Loss	$-51.91M	$-81.04M	$-94.9M
Cost of Revenue	$43.6M	$42.5M	$38.48M
Net Cash Flow	$-85.73M	$33.44M	$25.69M
PE Ratio

Splits
Sep 26, 2013	1:100
Apr 06, 2010	24:1